Please complete the CAPTCHA to continue
@genethon.fr
✓
2 phones found area 425 and 316
✓
LinkedIn matched
A concise factual answer block for searchers comparing this professional profile.
Frederic Revah is listed as CEO Genethon Gene Therapy for Rare Diseases at Genethon, based in Greater Paris Metropolitan Region, France, France. AeroLeads shows a work email signal at genethon.fr, phone signal with area code 425, 316, and a matched LinkedIn profile for Frederic Revah.
Frederic Revah previously worked as Chief Executive Officer at Genethon and Board Member at Yposkesi. Frederic Revah holds Engineer'S Degree from École Polytechnique.
This section adds company-level context without repeating Frederic Revah's masked contact details.
AeroLeads found 2 current-domain work email signals for Frederic Revah. Compare company email patterns before reaching out.
Frederic Revah is a CEO Genethon Gene Therapy for Rare Diseases at Genethon. He possess expertise in drug discovery, biotechnology, clinical development, pharmaceutical industry, lifesciences and 19 more skills.
Listed skills include Drug Discovery, Biotechnology, Clinical Development, Pharmaceutical Industry, and 20 others.
Company context helps verify the profile and gives searchers a useful next step.
A career timeline built from the work history available for this profile.
Évry, Île-de-France, FR
Genethon is one of the world’s leading R&D organizations for the development of gene therapies for genetic diseases. Genethon is a not-for-profit organization created and funded by the patient association AFM-Telethon.
Created in 1990, listed on NYSE Euronext, Cerep has been a leader in Drug Discovery services, combining an original business model of profitable services with drug discovery. With a center for in vitro pharmacology and drug profiling in Poitiers (France), one dedicated to ADMET in Seattle (Wash.), to combinatorial and medicinal chemistry as well as in vivo.
FR
A Franco-Israeli company in the field of oncology and onco-dermatology, developing at clinical and preclinical stage original drugs targeted to specific energy metabolism of cancer cells.
Celle L'EVESCAULT, Nouvelle Aquitaine - Vienne, FR
Created in 1990, listed on NYSE Euronext, Cerep has been a leader in Drug Discovery services, combining an original business model of profitable services with drug discovery. With a center for in vitro pharmacology and drug profiling in Poitiers (France), one dedicated to ADMET in Seattle (Wash.), to combinatorial and medicinal chemistry as well as in vivo.
Head of the CNS Gene Therapy department with programs for Parkinson's disease, Amyotrophic Lateral Sclerosis, Spinal cord injury, EpilepsyHead of Neuropharmacology with programs in Alzheimer's disease, Parkinson's disease, Amyotrophic Lateral Sclerosis.
Paris, FR
Molecular Neurobiology, in the Laboratory of Prof. Jean Pierre Changeux
Quick answers generated from the profile data available on this page.
Frederic Revah works for Genethon.
Frederic Revah is listed as CEO Genethon Gene Therapy for Rare Diseases at Genethon.
AeroLeads has found 2 work email signals at @genethon.fr for Frederic Revah at Genethon.
AeroLeads has found 2 phone signal(s) with area code 425, 316 for Frederic Revah at Genethon.
Frederic Revah is based in Greater Paris Metropolitan Region, France, France while working with Genethon.
Frederic Revah has worked for Genethon, Yposkesi, Atamyo Therapeutics, Cerep, and Sepal Pharma.
You can use AeroLeads to view verified contact signals for Frederic Revah at Genethon, including work email, phone, and LinkedIn data when available.
Frederic Revah holds Engineer'S Degree from École Polytechnique.
Frederic Revah is listed with skills including Drug Discovery, Biotechnology, Clinical Development, Pharmaceutical Industry, Lifesciences, Drug Development, Technology Transfer, and Molecular Biology.
Search by job title, company, industry, location, and seniority. Export verified B2B contact data when you need it.
Start free trial Search contacts